{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T21:20:23Z","timestamp":1722806423739},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,6,15]],"date-time":"2012-06-15T00:00:00Z","timestamp":1339718400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Steroid receptor coactivators (SRCs) may modulate estrogen receptor (ER) activity and the response to endocrine treatment in breast cancer, in part through interaction with growth factor receptor signaling pathways. In the present study the effects of tamoxifen treatment on the expression of SRCs and human epidermal growth factor receptors (HERs) were examined in an animal model of ER positive breast cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Sprague-Dawley rats with DMBA-induced breast cancer were randomized to 14\u2009days of oral tamoxifen 40\u2009mg\/kg bodyweight\/day or vehicle only (controls). Tumors were measured throughout the study period. Blood samples and tumor tissue were collected at sacrifice and tamoxifen and its main metabolites were quantified using LC-MS\/MS. The gene expression in tumor of SRC-1, SRC-2\/transcription intermediary factor-2 (TIF-2), SRC-3\/amplified in breast cancer 1 (AIB1), ER, HER-1, -2, -3 and HER-4, as well as the transcription factor Ets-2, was measured by real-time RT-PCR. Protein levels were further assessed by Western blotting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Tamoxifen and its main metabolites were detected at high concentrations in serum and accumulated in tumor tissue in up to tenfolds the concentration in serum. Mean tumor volume\/rat decreased in the tamoxifen treated group, but continued to increase in controls. The mRNA expression levels of SRC-1 (<jats:italic>P<\/jats:italic>\u2009=\u20090.035), SRC-2\/TIF-2 (<jats:italic>P<\/jats:italic>\u2009=\u20090.002), HER-2 (<jats:italic>P<\/jats:italic>\u2009=\u20090.035) and HER-3 (<jats:italic>P<\/jats:italic>\u2009=\u20090.006) were significantly higher in tamoxifen treated tumors compared to controls, and the results were confirmed at the protein level using Western blotting. SRC-3\/AIB1 protein was also higher in tamoxifen treated tumors. SRC-1 and SRC-2\/TIF-2 mRNA levels were positively correlated with each other and with HER-2 (<jats:italic>P<\/jats:italic>\u2009\u2264\u20090.001), and the HER-2 mRNA expression correlated with the levels of the other three HER family members (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Furthermore, SRC-3\/AIB1 and HER-4 were positively correlated with each other and Ets-2 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The expression of SRCs and HER-2 and -3 is stimulated by tamoxifen treatment in DMBA-induced breast cancer. Stimulation and positive correlation of coactivators and HERs may represent an early response to endocrine treatment. The role of SRCs and HER-2 and -3 should be further studied in order to evaluate their effects on response to long-term tamoxifen treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-12-247","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T13:45:54Z","timestamp":1340804754000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer"],"prefix":"10.1186","volume":"12","author":[{"given":"Line L Haugan","family":"Moi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne Hauglid","family":"Fl\u00e5geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Gjerde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Therese Halvorsen","family":"R\u00f8st","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oddrun Anita","family":"Gudbrandsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernst A","family":"Lien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Mellgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,15]]},"reference":[{"key":"3227_CR1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S1043-2760(01)00436-2","volume":"12","author":"JS Foster","year":"2001","unstructured":"Foster JS, Henley DC, Ahamed S, Wimalasena J: Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol Metab. 2001, 12: 320-327. 10.1016\/S1043-2760(01)00436-2.","journal-title":"Trends Endocrinol Metab"},{"key":"3227_CR2","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717.","journal-title":"Lancet"},{"key":"3227_CR3","doi-asserted-by":"publisher","first-page":"5815","DOI":"10.1200\/JCO.2007.11.3886","volume":"36","author":"VC Jordan","year":"2007","unstructured":"Jordan VC, O\u2019Malley BW: Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol. 2007, 36: 5815-5824.","journal-title":"J Clin Oncol"},{"key":"3227_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1210\/me.2009-0276","volume":"24","author":"DM Lonard","year":"2010","unstructured":"Lonard DM, Kumar R, O'Malley BW: Minireview: the SRC family of coactivators: an entr\u00e9e to understanding a subset of polygenic diseases?. Mol Endocrinol. 2010, 24: 279-285. 10.1210\/me.2009-0276.","journal-title":"Mol Endocrinol"},{"key":"3227_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1023\/A:1022930710850","volume":"78","author":"G Hudelist","year":"2003","unstructured":"Hudelist G, Czerwenka K, Kubista E, Marton E, Pischinger K, Singer CF: Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res Treat. 2003, 78: 193-204. 10.1023\/A:1022930710850.","journal-title":"Breast Cancer Res Treat"},{"key":"3227_CR6","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1158\/1078-0432.CCR-09-1859","volume":"16","author":"LL Haugan Moi","year":"2010","unstructured":"Haugan Moi LL, Fl\u00e5geng MH, Gandini S, Guerrieri-Gonzaga A, Bonanni B, Lazzeroni M, Gjerde J, Lien EA, DeCensi A, Mellgren G: Effect of low dose tamoxifen on Steroid Receptor Coactivator 3\/Amplified in Breast Cancer 1 in normal and malignant human breast tissue. Clin Cancer Res. 2010, 16: 2176-2186. 10.1158\/1078-0432.CCR-09-1859.","journal-title":"Clin Cancer Res"},{"key":"3227_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1210\/en.2010-1012","volume":"152","author":"JP Lydon","year":"2011","unstructured":"Lydon JP, O'Malley BW: Minireview: steroid receptor coactivator-3: a multifarious coregulator in mammary gland metastasis. Endocrinology. 2011, 152: 19-25. 10.1210\/en.2010-1012.","journal-title":"Endocrinology"},{"key":"3227_CR8","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1126\/science.277.5328.965","volume":"277","author":"SL Anzick","year":"1997","unstructured":"Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 1997, 277: 965-968. 10.1126\/science.277.5328.965.","journal-title":"Science"},{"key":"3227_CR9","first-page":"6266","volume":"60","author":"LC Murphy","year":"2000","unstructured":"Murphy LC, Simon SL, Parkes A, Leygue E, Dotzlaw H, Snell L, Troup S, Adeyinka A, Watson PH: Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res. 2000, 60: 6266-6271.","journal-title":"Cancer Res"},{"key":"3227_CR10","first-page":"903","volume":"61","author":"T Bouras","year":"2001","unstructured":"Bouras T, Southey MC, Venter DJ: Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2\/neu. Cancer Res. 2001, 61: 903-907.","journal-title":"Cancer Res"},{"key":"3227_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1023\/A:1017910924390","volume":"68","author":"HJ List","year":"2001","unstructured":"List HJ, Reiter R, Singh B, Wellstein A, Riegel AT: Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat. 2001, 68: 21-28. 10.1023\/A:1017910924390.","journal-title":"Breast Cancer Res Treat"},{"key":"3227_CR12","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/jnci\/djh166","volume":"96","author":"J Shou","year":"2004","unstructured":"Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R: Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2\/neu cross-talk in ER\/HER2-positive breast cancer. J Nat Cancer Inst. 2004, 96: 926-935. 10.1093\/jnci\/djh166.","journal-title":"J Nat Cancer Inst"},{"key":"3227_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ccr.2006.09.015","volume":"10","author":"LH Wang","year":"2006","unstructured":"Wang LH, Yang XY, Zhang X, An P, Kim HJ, Huang J, Clarke R, Osborne CK, Inman JK, Appella E, Farrar WL: Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell. 2006, 10: 487-499. 10.1016\/j.ccr.2006.09.015.","journal-title":"Cancer Cell"},{"key":"3227_CR14","doi-asserted-by":"publisher","first-page":"26897","DOI":"10.1074\/jbc.M705596200","volume":"282","author":"D Kressler","year":"2007","unstructured":"Kressler D, Hock MB, Kralli A: Coactivators PGC-1b and SRC-1 interact functionally to promote the agonist activity of the selective estrogen receptor modulator tamoxifen. J Biol Chem. 2007, 282: 26897-26907. 10.1074\/jbc.M705596200.","journal-title":"J Biol Chem"},{"key":"3227_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/jnci\/95.5.353","volume":"95","author":"CK Osborne","year":"2003","unstructured":"Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2\/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003, 95: 353-361. 10.1093\/jnci\/95.5.353.","journal-title":"J Natl Cancer Inst"},{"key":"3227_CR16","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1136\/jcp.2004.016733","volume":"57","author":"FJ Fleming","year":"2004","unstructured":"Fleming FJ, Myers E, Kelly G, Crotty TB, McDermott EW, O\u2019Higgins NJ, Hill ADK, Young LS: Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J Clin Pathol. 2004, 57: 1069-1074. 10.1136\/jcp.2004.016733.","journal-title":"J Clin Pathol"},{"key":"3227_CR17","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1158\/1078-0432.CCR-08-1649","volume":"15","author":"AM Redmond","year":"2009","unstructured":"Redmond AM, Bane FT, Stafford AT, McIlroy M, Dillon MF, Crotty TB, Hill AD, Young LS: Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clin Cancer Res. 2009, 15: 2098-2106. 10.1158\/1078-0432.CCR-08-1649.","journal-title":"Clin Cancer Res"},{"key":"3227_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/sj.bjc.6605324","volume":"101","author":"MH Fl\u00e5geng","year":"2009","unstructured":"Fl\u00e5geng MH, Haugan Moi LL, Dixon JM, Geisler J, Lien EA, Miller WR, L\u00f8nning PE, Mellgren G: Nuclear receptor coactivators and HER-2\/neu are upregulated in breast cancer patients during neoadjuvant treatment with aromatase inhibitors. Brit J Cancer. 2009, 101: 253-260.","journal-title":"Brit J Cancer"},{"key":"3227_CR19","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/189204a0","volume":"189","author":"C Huggins","year":"1961","unstructured":"Huggins C, Grand LC, Brilliantes FP: Mammary cancer induced by a single feeding of polynuclear hydrocarbons, and its suppression. Nature. 1961, 189: 204-207. 10.1038\/189204a0.","journal-title":"Nature"},{"key":"3227_CR20","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","volume":"19","author":"MA Olayioye","year":"2000","unstructured":"Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: receptor dimerization in development and cancer. EMBO J. 2000, 19: 3159-3167. 10.1093\/emboj\/19.13.3159.","journal-title":"EMBO J"},{"key":"3227_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.chroma.2005.01.004","volume":"1082","author":"J Gjerde","year":"2005","unstructured":"Gjerde J, Kisanga ER, Hauglid M, Holm PI, Mellgren G, Lien EA: Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2005, 1082: 6-14. 10.1016\/j.chroma.2005.01.004.","journal-title":"J Chromatogr A"},{"key":"3227_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0960-0760(03)00051-7","volume":"84","author":"ER Kisanga","year":"2003","unstructured":"Kisanga ER, Gjerde J, Schj\u00f8tt J, Mellgren G, Lien EA: Tamoxifen administration and metabolism in nude mice and nude rats. J Steroid Biochem Mol Biol. 2003, 84: 361-367. 10.1016\/S0960-0760(03)00051-7.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3227_CR23","first-page":"4837","volume":"51","author":"EA Lien","year":"1991","unstructured":"Lien EA, Solheim E, Ueland PM: Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 1991, 51: 4837-4844.","journal-title":"Cancer Res"},{"key":"3227_CR24","doi-asserted-by":"publisher","first-page":"7147","DOI":"10.1038\/sj.onc.1205943","volume":"21","author":"KJ Lauritsen","year":"2002","unstructured":"Lauritsen KJ, List HJ, Reiter R, Wellstein A, Riegel AT: A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. Oncogene. 2002, 21: 7147-7155. 10.1038\/sj.onc.1205943.","journal-title":"Oncogene"},{"key":"3227_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1128\/MCB.24.1.14-24.2004","volume":"24","author":"DM Lonard","year":"2004","unstructured":"Lonard DM, Tsai SY, O\u2019Malley BW: Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins. Mol Cell Biol. 2004, 24: 14-24. 10.1128\/MCB.24.1.14-24.2004.","journal-title":"Mol Cell Biol"},{"key":"3227_CR26","first-page":"1001","volume":"5","author":"C Dati","year":"1990","unstructured":"Dati C, Antoniotti S, Tavema D, Perroteau I, De Bortoli M: Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene. 1990, 5: 1001-1006.","journal-title":"Oncogene"},{"key":"3227_CR27","first-page":"3947","volume":"50","author":"LD Read","year":"1990","unstructured":"Read LD, Keith D, Slamon DJ, Katzenellenbogen BS: Hormonal modulation of HER-2\/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res. 1990, 50: 3947-3951.","journal-title":"Cancer Res"},{"key":"3227_CR28","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/bjc.1994.454","volume":"70","author":"S Antoniotti","year":"1994","unstructured":"Antoniotti S, Tavema D, Maggiora P, Sapei ML, Hynes NE, DeBortoli M: Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms. Br J Cancer. 1994, 70: 1095-1101. 10.1038\/bjc.1994.454.","journal-title":"Br J Cancer"},{"key":"3227_CR29","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/sj.onc.1203416","volume":"19","author":"SP Newman","year":"2000","unstructured":"Newman SP, Bates NP, Vernimmen D, Parker MG, Hurst HC: Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene. 2000, 19: 490-497. 10.1038\/sj.onc.1203416.","journal-title":"Oncogene"},{"key":"3227_CR30","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nature07483","volume":"456","author":"A Hurtado","year":"2008","unstructured":"Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS: Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature. 2008, 456: 663-666. 10.1038\/nature07483.","journal-title":"Nature"},{"key":"3227_CR31","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1210\/en.2002-220620","volume":"144","author":"JM Knowlden","year":"2003","unstructured":"Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI: Elevated levels of epidermal growth factor receptor\/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology. 2003, 144: 1032-1044. 10.1210\/en.2002-220620.","journal-title":"Endocrinology"},{"key":"3227_CR32","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/emboj\/16.7.1647","volume":"16","author":"D Graus-Porta","year":"1997","unstructured":"Graus-Porta D, Beerli RR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997, 16: 1647-1655. 10.1093\/emboj\/16.7.1647.","journal-title":"EMBO J"},{"key":"3227_CR33","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/sj.onc.1202091","volume":"17","author":"MP DiGiovanna","year":"1998","unstructured":"DiGiovanna MP, Lerman MA, Coffey RJ, Muller WJ, Cardiff RD, Stern DF: Active signaling by Neu in transgenic mice. Oncogene. 1998, 17: 1877-1884. 10.1038\/sj.onc.1202091.","journal-title":"Oncogene"},{"key":"3227_CR34","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1093\/emboj\/18.8.2149","volume":"18","author":"PM Siegel","year":"1999","unstructured":"Siegel PM, Ryan ED, Cardiff RD, Muller WJ: Elevated expression of activated forms of Neu\/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 1999, 18: 2149-2164. 10.1093\/emboj\/18.8.2149.","journal-title":"EMBO J"},{"key":"3227_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1023\/A:1024929522376","volume":"80","author":"G Hudelist","year":"2003","unstructured":"Hudelist G, Singer CF, Manavi M, Pischinger K, Kubista E, Czerwenka K: Co-expression of ErbB-family members in human breast cancer: Her-2\/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat. 2003, 80: 353-361. 10.1023\/A:1024929522376.","journal-title":"Breast Cancer Res Treat"},{"key":"3227_CR36","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1038\/sj.onc.1203470","volume":"19","author":"RM Neve","year":"2000","unstructured":"Neve RM, Sutterl\u00fcty H, Pullen N, Lane HA, Daly JM, Krek W, Hynes NE: Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene. 2000, 19: 1647-1656. 10.1038\/sj.onc.1203470.","journal-title":"Oncogene"},{"key":"3227_CR37","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1002\/ijc.22423","volume":"120","author":"B Liu","year":"2007","unstructured":"Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD: Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer. 2007, 120: 1874-1882. 10.1002\/ijc.22423.","journal-title":"Int J Cancer"},{"key":"3227_CR38","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-04-1192","volume":"11","author":"E Myers","year":"2005","unstructured":"Myers E, Hill ADK, Kelly G, McDermott EW, O\u2019Higgins NJ, Buggy Y, Young LS: Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin Cancer Res. 2005, 11: 2111-2122. 10.1158\/1078-0432.CCR-04-1192.","journal-title":"Clin Cancer Res"},{"key":"3227_CR39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1073\/pnas.0808703105","volume":"106","author":"S Wang","year":"2009","unstructured":"Wang S, Yuan Y, Liao L, Kuang SQ, Tien JC, O\u2019Malley BW, Xu J: Disruption of the SRC-1 gene mice suppresses breast cancer metastasis without affecting primary tumor formation. Proc Natl Acad Sci US. 2009, 106: 151-156. 10.1073\/pnas.0808703105.","journal-title":"Proc Natl Acad Sci US"},{"key":"3227_CR40","first-page":"2435","volume":"10","author":"RJ Pietras","year":"1995","unstructured":"Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995, 10: 2435-2446.","journal-title":"Oncogene"},{"key":"3227_CR41","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1677\/erc.1.01222","volume":"13","author":"M McIlroy","year":"2006","unstructured":"McIlroy M, Fleming FJ, Buggy Y, Hill ADK, Young LS: Tamoxifen induces ER-alpha \u2013 SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence. Endocr Relat Cancer. 2006, 13: 1135-1145. 10.1677\/erc.1.01222.","journal-title":"Endocr Relat Cancer"},{"key":"3227_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF01961241","volume":"24","author":"CC Benz","year":"1992","unstructured":"Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2\/neu. Breast Cancer Res Treat. 1992, 24: 85-95. 10.1007\/BF01961241.","journal-title":"Breast Cancer Res Treat"},{"key":"3227_CR43","first-page":"1263","volume":"5","author":"DL Miller","year":"1994","unstructured":"Miller DL, El-Ashry D, Cheville AL, Liu Y, McLeskey SW, Kern FG: Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Differ. 1994, 5: 1263-1274.","journal-title":"Cell Growth Differ"},{"key":"3227_CR44","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.bbrc.2009.01.155","volume":"380","author":"W Zhao","year":"2009","unstructured":"Zhao W, Zhang Q, Kang X, Jin S, Lou C: AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells. Biochem Biophys Res Commun. 2009, 380: 699-704. 10.1016\/j.bbrc.2009.01.155.","journal-title":"Biochem Biophys Res Commun"},{"key":"3227_CR45","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1210\/mend.15.1.0590","volume":"15","author":"W Feng","year":"2001","unstructured":"Feng W, Webb P, Nguyen P, Liu X, Li J, Karin M, Kushner PJ: Potentiation of estrogen receptor activation function 1 (AF-1) by Src\/JNK through a serine 118-independent pathway. Mol Endocrinol. 2001, 15: 32-45. 10.1210\/me.15.1.32.","journal-title":"Mol Endocrinol"},{"key":"3227_CR46","doi-asserted-by":"publisher","first-page":"8720","DOI":"10.1128\/MCB.20.23.8720-8730.2000","volume":"20","author":"BG Rowan","year":"2000","unstructured":"Rowan BG, Garrison N, Weigel NL, O\u2019Malley BW: 8-bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Mol Cell Biol. 2000, 20: 8720-8730. 10.1128\/MCB.20.23.8720-8730.2000.","journal-title":"Mol Cell Biol"},{"key":"3227_CR47","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.1128\/MCB.20.14.5041-5047.2000","volume":"20","author":"J Font De Mora","year":"2000","unstructured":"Font De Mora J, Brown M: AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol. 2000, 20: 5041-5047. 10.1128\/MCB.20.14.5041-5047.2000.","journal-title":"Mol Cell Biol"},{"key":"3227_CR48","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1128\/MCB.22.10.3549-3561.2002","volume":"22","author":"RC Wu","year":"2002","unstructured":"Wu RC, Qin J, Hashimoto Y, Wong J, Xu J, Tsai SY, Tsai MJ, O\u2019Malley BW: Regulation of SRC-3 (pCIP\/ACTR\/AIB-1\/RAC-3\/TRAM-1) coactivator activity by I\u039aB kinase. Mol Cell Biol. 2002, 22: 3549-3561. 10.1128\/MCB.22.10.3549-3561.2002.","journal-title":"Mol Cell Biol"},{"key":"3227_CR49","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.molcel.2004.08.019","volume":"15","author":"RC Wu","year":"2004","unstructured":"Wu RC, Qin J, Yi P, Wong J, Tsai SY, Tsai MJ, O\u2019Malley BW: Selective phosphorylation of the SRC-3\/AIB coactivator integrate genomic responses to multiple cellular signaling pathways. Mol Cell. 2004, 15: 937-949. 10.1016\/j.molcel.2004.08.019.","journal-title":"Mol Cell"},{"key":"3227_CR50","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0022-4731(88)90013-1","volume":"31","author":"JR Pasqualini","year":"1988","unstructured":"Pasqualini JR, Sumida C, Giambiagi N: Pharmacodynamics and biological effects of antiestrogens in different models. J Steroid Biochem. 1988, 31: 613-643. 10.1016\/0022-4731(88)90013-1.","journal-title":"J Steroid Biochem"},{"key":"3227_CR51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1023\/B:BREA.0000025406.31193.e8","volume":"85","author":"MD Johnson","year":"2004","unstructured":"Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004, 85: 151-159. 10.1023\/B:BREA.0000025406.31193.e8.","journal-title":"Breast Cancer Res Treat"},{"key":"3227_CR52","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/annonc\/mdm434","volume":"19","author":"J Gjerde","year":"2008","unstructured":"Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, Mellgren G, Steen VM, Lien EA: Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol. 2008, 19: 56-61.","journal-title":"Ann Oncol"},{"key":"3227_CR53","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1017\/S1462399408000896","volume":"10","author":"V Stearns","year":"2008","unstructured":"Stearns V, Rae JM: Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?. Expert Rev Mol Med. 2008, 10: e34-","journal-title":"Expert Rev Mol Med"},{"key":"3227_CR54","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1124\/dmd.104.000802","volume":"33","author":"P Parte","year":"2005","unstructured":"Parte P, Kupfer D: Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab Dispos. 2005, 33: 1446-1452. 10.1124\/dmd.104.000802.","journal-title":"Drug Metab Dispos"},{"key":"3227_CR55","first-page":"2304","volume":"48","author":"EA Lien","year":"1988","unstructured":"Lien EA, Solheim E, Kvinnsland S, Ueland PM: Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res. 1988, 48: 2304-2308.","journal-title":"Cancer Res"},{"key":"3227_CR56","first-page":"2175","volume":"49","author":"EA Lien","year":"1989","unstructured":"Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM: Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 1989, 49: 2175-2183.","journal-title":"Cancer Res"},{"key":"3227_CR57","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jsbmb.2004.12.037","volume":"94","author":"ER Kisanga","year":"2005","unstructured":"Kisanga ER, Haugan Moi LL, Gjerde J, Mellgren G, Lien EA: Induction of hepatic drug-metabolising enzymes and tamoxifen metabolite profile in relation to administration route during low-dose treatment in nude rats. J Steroid Biochem Mol Biol. 2005, 94: 489-498. 10.1016\/j.jsbmb.2004.12.037.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3227_CR58","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1359\/jbmr.080319","volume":"23","author":"E Karimian","year":"2008","unstructured":"Karimian E, Chagin AS, Gjerde J, Heino T, Lien EA, Ohlsson C, S\u00e4vendahl L: Tamoxifen impairs both longitudinal and cortical bone growth in young male rats. J Bone Miner Res. 2008, 23: 1267-1277. 10.1359\/jbmr.080319.","journal-title":"J Bone Miner Res"},{"key":"3227_CR59","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1158\/1078-0432.CCR-03-0538","volume":"10","author":"ER Kisanga","year":"2004","unstructured":"Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C, Serrano D, Pelosi G, Decensi A, Lien EA: Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res. 2004, 10: 2336-2343. 10.1158\/1078-0432.CCR-03-0538.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-12-247\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T20:41:21Z","timestamp":1630615281000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-12-247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,15]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["3227"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-12-247","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,15]]},"assertion":[{"value":"28 November 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"247"}}